| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| María Teresa Guarro Carreras, Luis Jiménez Suárez, Laura Lago García, Laura Montes Reula, Adrián Neyra Del Rosario, Francisco Acoidan Rodríguez Batista, Miguel Velasco Santos, Juan L Prados-Ojeda, Marina Diaz-Marsà, Manuel Martín-Carrasco, Antonio Cardena. Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive, and cognitive symptoms in schizophrenia and of dual psychosis. Drugs in context. vol 13. 2024-08-12. PMID:39131604. |
towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive, and cognitive symptoms in schizophrenia and of dual psychosis. |
2024-08-12 |
2024-08-14 |
Not clear |
| María Teresa Guarro Carreras, Luis Jiménez Suárez, Laura Lago García, Laura Montes Reula, Adrián Neyra Del Rosario, Francisco Acoidan Rodríguez Batista, Miguel Velasco Santos, Juan L Prados-Ojeda, Marina Diaz-Marsà, Manuel Martín-Carrasco, Antonio Cardena. Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive, and cognitive symptoms in schizophrenia and of dual psychosis. Drugs in context. vol 13. 2024-08-12. PMID:39131604. |
the management of schizophrenia necessitates a comprehensive treatment paradigm that considers individual patient nuances and the efficacy of lurasidone in addressing schizophrenia symptoms, particularly at elevated dosages. |
2024-08-12 |
2024-08-14 |
Not clear |
| María Teresa Guarro Carreras, Luis Jiménez Suárez, Laura Lago García, Laura Montes Reula, Adrián Neyra Del Rosario, Francisco Acoidan Rodríguez Batista, Miguel Velasco Santos, Juan L Prados-Ojeda, Marina Diaz-Marsà, Manuel Martín-Carrasco, Antonio Cardena. Towards full recovery with lurasidone: effective doses in the treatment of agitation, affective, positive, and cognitive symptoms in schizophrenia and of dual psychosis. Drugs in context. vol 13. 2024-08-12. PMID:39131604. |
finally, a series of clinical cases is presented, highlighting benefits of lurasidone in terms of cognitive function, functional recovery and other therapeutic aspects for the management of schizophrenia. |
2024-08-12 |
2024-08-14 |
Not clear |
| Se Hyun Kim, Do-Un Jung, Do Hoon Kim, Jung Sik Lee, Kyoung-Uk Lee, Seunghee Won, Bong Ju Lee, Sung-Gon Kim, Sungwon Roh, Jong-Ik Park, Minah Kim, Sung Won Jung, Hong Seok Oh, Han-Yong Jung, Sang Hoon Kim, Hyun Seung Chee, Jong-Woo Paik, Kyu Young Lee, Soo In Kim, Seung-Hwan Lee, Eun-Jin Cheon, Hye-Geum Kim, Heon-Jeong Lee, In Won Chung, Joonho Choi, Min-Hyuk Kim, Seong-Jin Cho, HyunChul Youn, Jhin-Goo Chang, Hoo Rim Song, Euitae Kim, Won-Hyoung Kim, Chul Eung Kim, Doo-Heum Park, Byung-Ook Lee, Jungsun Lee, Seung-Yup Lee, Nuree Kang, Hee Yeon Jun. Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial. Psychiatry investigation. vol 21. issue 7. 2024-08-01. PMID:39089702. |
efficacy and safety of lurasidone vs. quetiapine xr in acutely psychotic patients with schizophrenia in korea: a randomized, double-blind, active-controlled trial. |
2024-08-01 |
2024-08-05 |
Not clear |
| Se Hyun Kim, Do-Un Jung, Do Hoon Kim, Jung Sik Lee, Kyoung-Uk Lee, Seunghee Won, Bong Ju Lee, Sung-Gon Kim, Sungwon Roh, Jong-Ik Park, Minah Kim, Sung Won Jung, Hong Seok Oh, Han-Yong Jung, Sang Hoon Kim, Hyun Seung Chee, Jong-Woo Paik, Kyu Young Lee, Soo In Kim, Seung-Hwan Lee, Eun-Jin Cheon, Hye-Geum Kim, Heon-Jeong Lee, In Won Chung, Joonho Choi, Min-Hyuk Kim, Seong-Jin Cho, HyunChul Youn, Jhin-Goo Chang, Hoo Rim Song, Euitae Kim, Won-Hyoung Kim, Chul Eung Kim, Doo-Heum Park, Byung-Ook Lee, Jungsun Lee, Seung-Yup Lee, Nuree Kang, Hee Yeon Jun. Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial. Psychiatry investigation. vol 21. issue 7. 2024-08-01. PMID:39089702. |
this study was performed to evaluate the efficacy and safety of lurasidone (160 mg/day) compared to quetiapine xr (qxr; 600 mg/day) in the treatment of acutely psychotic patients with schizophrenia. |
2024-08-01 |
2024-08-05 |
Not clear |
| Hidenori Maruyama, Fumiya Sano, Reiko Sakaguchi, Keisuke Okamoto, Itaru Miur. Effect of Lurasidone on Life Engagement in Schizophrenia: Post-Hoc Analysis of the JEWEL Study. Neuropsychiatric disease and treatment. vol 20. 2024-07-29. PMID:39072313. |
effect of lurasidone on life engagement in schizophrenia: post-hoc analysis of the jewel study. |
2024-07-29 |
2024-08-02 |
Not clear |
| Hidenori Maruyama, Fumiya Sano, Reiko Sakaguchi, Keisuke Okamoto, Itaru Miur. Effect of Lurasidone on Life Engagement in Schizophrenia: Post-Hoc Analysis of the JEWEL Study. Neuropsychiatric disease and treatment. vol 20. 2024-07-29. PMID:39072313. |
to evaluate the effect of lurasidone on a new, patient life engagement scale in schizophrenia. |
2024-07-29 |
2024-08-02 |
Not clear |
| Leslie Citrome, Elena Álvarez-Barón, Irene Gabarda-Inat, Karthinathan Thangavelu, Michael Tocc. The specific anti-hostility effect of lurasidone in patients with an acute exacerbation of schizophrenia: results of pooled post hoc analyses in adolescents and adults. International clinical psychopharmacology. 2024-07-25. PMID:39052354. |
the specific anti-hostility effect of lurasidone in patients with an acute exacerbation of schizophrenia: results of pooled post hoc analyses in adolescents and adults. |
2024-07-25 |
2024-07-28 |
Not clear |
| Leslie Citrome, Elena Álvarez-Barón, Irene Gabarda-Inat, Karthinathan Thangavelu, Michael Tocc. The specific anti-hostility effect of lurasidone in patients with an acute exacerbation of schizophrenia: results of pooled post hoc analyses in adolescents and adults. International clinical psychopharmacology. 2024-07-25. PMID:39052354. |
two post hoc analyses were performed to examine the efficacy of lurasidone for reducing hostility in patients with schizophrenia. |
2024-07-25 |
2024-07-28 |
Not clear |
| Aleksandr Reznik, Timur Syunyakov, Inessa Akhmerova, Daniil Butylin, Anastasia Vasilenko, Anton Gvozdetckii, Tagir Gizatullin, Galina Gilmanshina, Egor Golosov, Sergey Kolchev, Lidiya Linova, Daniil Miron, Aleksandr Mudrak, Igor Oleichik, Stepan Sizov, Elena Tarakanova, Olga Chesnokov. Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression. Consortium psychiatricum. vol 3. issue 3. 2024-07-24. PMID:39044917. |
clinical effectiveness of lurasidone monotherapy in patients with acute episodes of schizophrenia and associated symptoms of depression. |
2024-07-24 |
2024-07-26 |
Not clear |
| Aleksandr Reznik, Timur Syunyakov, Inessa Akhmerova, Daniil Butylin, Anastasia Vasilenko, Anton Gvozdetckii, Tagir Gizatullin, Galina Gilmanshina, Egor Golosov, Sergey Kolchev, Lidiya Linova, Daniil Miron, Aleksandr Mudrak, Igor Oleichik, Stepan Sizov, Elena Tarakanova, Olga Chesnokov. Clinical Effectiveness of Lurasidone Monotherapy in Patients with Acute Episodes of Schizophrenia and Associated Symptoms of Depression. Consortium psychiatricum. vol 3. issue 3. 2024-07-24. PMID:39044917. |
we endeavored to evaluate the efficacy of lurasidone at doses of 40-160 mg per day on symptoms of schizophrenia associated with symptoms of depression in real clinical practice in a russian patient population. |
2024-07-24 |
2024-07-26 |
Not clear |
| Fabrizio Calisti, Michael Tocco, Yongcai Mao, Robert Goldma. Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies. Annals of general psychiatry. vol 23. issue 1. 2024-07-17. PMID:39020362. |
long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies. |
2024-07-17 |
2024-07-20 |
Not clear |
| Fabrizio Calisti, Michael Tocco, Yongcai Mao, Robert Goldma. Long-term safety and effectiveness of lurasidone in adolescents and young adults with schizophrenia: pooled post hoc analyses of two 12-month extension studies. Annals of general psychiatry. vol 23. issue 1. 2024-07-17. PMID:39020362. |
the aim of this analysis was to evaluate the long-term safety and effectiveness of lurasidone in the treatment of schizophrenia in adolescents and young adults (13-25). |
2024-07-17 |
2024-07-20 |
Not clear |
| Shan Gao, Ling Fan, Zhigang Yu, Xingxing Xi. Efficacy and safety of lurasidone for schizophrenia: A systematic review and meta‑analysis of eight short‑term, randomized, double‑blind, placebo‑controlled clinical trials. Biomedical reports. vol 20. issue 6. 2024-04-29. PMID:38682090. |
efficacy and safety of lurasidone for schizophrenia: a systematic review and meta‑analysis of eight short‑term, randomized, double‑blind, placebo‑controlled clinical trials. |
2024-04-29 |
2024-05-01 |
Not clear |
| Shan Gao, Ling Fan, Zhigang Yu, Xingxing Xi. Efficacy and safety of lurasidone for schizophrenia: A systematic review and meta‑analysis of eight short‑term, randomized, double‑blind, placebo‑controlled clinical trials. Biomedical reports. vol 20. issue 6. 2024-04-29. PMID:38682090. |
the present study systematically assessed the efficacy and safety of lurasidone in the treatment of schizophrenia. |
2024-04-29 |
2024-05-01 |
Not clear |
| Shan Gao, Ling Fan, Zhigang Yu, Xingxing Xi. Efficacy and safety of lurasidone for schizophrenia: A systematic review and meta‑analysis of eight short‑term, randomized, double‑blind, placebo‑controlled clinical trials. Biomedical reports. vol 20. issue 6. 2024-04-29. PMID:38682090. |
clinical, double-blind, parallel, randomized controlled trials (rcts) of lurasidone in the treatment of schizophrenia were retrieved from pubmed\medline, ebsco, embase, cochrane library, ovid, web of science and related clinical trial registration websites up to may 2023. |
2024-04-29 |
2024-05-01 |
Not clear |
| Shan Gao, Ling Fan, Zhigang Yu, Xingxing Xi. Efficacy and safety of lurasidone for schizophrenia: A systematic review and meta‑analysis of eight short‑term, randomized, double‑blind, placebo‑controlled clinical trials. Biomedical reports. vol 20. issue 6. 2024-04-29. PMID:38682090. |
in conclusion, existing evidence suggests that the initial dose of lurasidone for schizophrenia can be adjusted to 80 mg. as the condition aggravates, the dose can be incrementally increased to 160 mg. a dose of 160 mg lurasidone is recommended as the most efficacious and safe dose for acute schizophrenia and the risk of occurrence of akathisia, nausea, somnolence and extrapyramidal disorder is still high when lurasidone is administered at a dose of 80-120 mg. |
2024-04-29 |
2024-05-01 |
Not clear |
| Andrea Fiorillo, Gaia Sampogna, Umberto Albert, Emi Bondi, Serafino De Giorgi, Andrea Fagiolini, Maurizio Pompili, Gianluca Serafini, Umberto Volpe, Antonio Vit. The Role of Lurasidone in Managing Depressive Symptoms in People with Schizophrenia: A Review. Brain sciences. vol 14. issue 3. 2024-03-28. PMID:38539614. |
the role of lurasidone in managing depressive symptoms in people with schizophrenia: a review. |
2024-03-28 |
2024-03-30 |
Not clear |
| Ryotaro Kubota, Satoru Ikezawa, Hideki Oi, Mari S Oba, Shoki Izumi, Ryoko Tsuno, Leona Adachi, Mako Miwa, Shunji Toya, Yohei Nishizato, Daisuke Haga, Tatsuro Iwane, Kazuyuki Nakagom. Valuable interaction with cognitive remediation and optimal antipsychotics for recovery in schizophrenia (VICTORY-S): study protocol for an interventional, open-label, randomized comparison of combined treatment with cognitive remediation and lurasidone or paliperidone. Frontiers in psychiatry. vol 14. 2024-02-21. PMID:38380376. |
valuable interaction with cognitive remediation and optimal antipsychotics for recovery in schizophrenia (victory-s): study protocol for an interventional, open-label, randomized comparison of combined treatment with cognitive remediation and lurasidone or paliperidone. |
2024-02-21 |
2024-02-23 |
Not clear |
| Itaru Miura, Fumiya Sano, Reiko Sakaguchi, Keisuke Okamoto, Hidenori Maruyam. Effect of Lurasidone on Social Functioning in Schizophrenia: Post Hoc Analysis of the JEWEL Study. The Journal of clinical psychiatry. vol 85. issue 1. 2024-02-01. PMID:38301186. |
effect of lurasidone on social functioning in schizophrenia: post hoc analysis of the jewel study. |
2024-02-01 |
2024-02-04 |
Not clear |